BR112014022624A2 - métodos e materiais para tratamento de doença de pompe - Google Patents

métodos e materiais para tratamento de doença de pompe

Info

Publication number
BR112014022624A2
BR112014022624A2 BR112014022624A BR112014022624A BR112014022624A2 BR 112014022624 A2 BR112014022624 A2 BR 112014022624A2 BR 112014022624 A BR112014022624 A BR 112014022624A BR 112014022624 A BR112014022624 A BR 112014022624A BR 112014022624 A2 BR112014022624 A2 BR 112014022624A2
Authority
BR
Brazil
Prior art keywords
amino acid
seq
set forth
acid sequence
polypeptides
Prior art date
Application number
BR112014022624A
Other languages
English (en)
Inventor
Noella Pynaert Gwenda
Robert Ludo Stout Jan
Camilla Telesphore Alida Maria; Piens Kathleen
Vervecken Wouter
Original Assignee
Oxyrane Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxyrane Uk Ltd filed Critical Oxyrane Uk Ltd
Publication of BR112014022624A2 publication Critical patent/BR112014022624A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

methods and materials for treatment of pompe's disease cross-reference to related applications this application claims the benefit of u.s. provisional application serial no. 61/611,485, filed march 15, 2012. the disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application. technical field this invention relates to isolated molecular complexes having acid alpha glucosidase activity, and more particularly to molecular complexes comprising at least two polypeptides derived by proteolysis from a precursor molecule, wherein the molecular complex includes at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell. background pompe's disease (also referred to as glycogen-storage disease type ii or acid-maltase deficiency) is a rare autosomal recessive disorder that results in an accumulation of glycogen in the lysosome due to a deficiency of acid alpha glucosidase (gaa). the build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, including the heart, skeletal muscles, live, and nervous system. pompe's disease is broadly classified into infantile and late onset forms. in the infantile-onset form, infants typically present during early infancy (4-8 months of age) with weakness and floppiness, and are unable to hold up their heads and cannot do other motor tasks common for their age, such as rolling over. without treatment, infants with pompe's disease usually die before 12 months of age due to heart failure and respiratory weakness. see, united pompe foundation. late onset forms (including juvenile and adult forms), have a later onset and progress more slowly than the infantile form. recombinant human gaa (myozyme(r) or lumizyme(r)) is used to treat pompe's disease. however, myozyme(r) or lumizyme(r) are both very expensive, with costs well over $300,000 per year. as such, there is a need for improved treatments for pompe's disease. summary in one aspect, this document features an isolated molecular complex having acid alpha glucosidase (gaa) activity and that includes at least two polypeptides (e.g., at least three or at least four polypeptides), each polypeptide having at least 85% (e.g., at least 90%, 95%, 99%, or 100%) sequence identity to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65). the molecular complex includes at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell. proteolysis of the amino acid sequence set forth in seq id no:1 further can include cleavage at one or more sites between amino acid 719 and amino acid 746 or cleavage at one or more sites between amino acid 137 and amino acid 151 of the amino acid sequence set forth in seq id no:1. proteolysis further can include cleavage at one or more sites between amino acid 719 and amino acid 746 of the amino acid sequence set forth in seq id no:1 and cleavage at one or more sites between amino acid 137 and amino acid 151 of the amino acid sequence set forth in seq id no:1. in any of the molecular complexes described herein, at least one of the polypeptides can include one or more phosphorylated n-glycans and the modification can include uncapping and demannosylation of at least one phosphorylated n-glycan. at least 40% (e.g., at least 60%, 80%, 90%, 95%, or 99%) of the n-glycans on at least one of the polypeptides can be uncapped and demannosylated. in any of the molecular complexes described herein, for one of the at least two polypeptides, the segment includes amino acids 22 to 57 of seq id no:1, and wherein for one of the at least two polypeptides, the segment includes amino acids 66 to 896 of seq id no:1. in any of the molecular complexes described herein containing at least three polypeptides, for one of the at least three polypeptides, the segment includes amino acids 22 to 57 of seq id no:1, wherein for one of the at least three polypeptides, the segment includes amino acids 66 to 726 of seq id no:1, and wherein for one of the at least three polypeptides, the segment includes amino acids 736 to 896 of seq id no:1. in any of the molecular complexes described herein containing at least four polypeptides, for one of the at least four polypeptides, the segment includes amino acids 22 to 57 of seq id no:1, wherein for one of the at least four polypeptides, the segment includes amino acids 66 to 143 of seq id no:1, wherein for one of the at least four polypeptides, the segment includes amino acids 158 to 726 of seq id no:1, and wherein for one of the at least four polypeptides, the segment includes amino acids 736 to 896 of seq id no:1. in any of the molecular complexes described herein, the at least one modification can include any one of the following fused to at least one polypeptide in the molecular complex: a ligand for an extracellular receptor, a targeting domain that binds an extracellular domain of a receptor on the surface of a target cell, a urokinase-type plasminogen receptor, or the recognition domain of human insulin-like growth factor ii. this document also features compositions that include any of the molecular complexes described herein, wherein the molecular complex is lyophilized. the composition can be packaged as a single use vial. this document also features a pharmaceutical composition that includes any of the molecular complexes described herein and a pharmaceutically acceptable carrier. the composition can be formulated for intravenous or subcutaneous administration. the composition can be formulated for intravenous infusion. in another aspect, this document features a method of treating pompe's disease. the method includes administering any of the compositions described herein to a patient diagnosed with pompe's disease. the patient can be diagnosed with infantile onset pompe's disease or late onset pompe's disease. this document also features a method for making a molecular complex. the method includes contacting a polypeptide having at least 85% sequence identity to the amino acid sequence set forth in seq id no:1 with a protease having at least 85% (e.g., at least 90%, at least 95%, at least 99%, or 100%) sequence identity to the amino acid sequence set forth in seq id no:8, wherein the protease cleaves the polypeptide at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65). the contacting step can be performed in vitro. this document also features a method for making a molecular complex that includes uncapped and demannosylated phosphorylated n-glycans. the method includes contacting a molecular complex with a mannosidase capable of (i) hydrolyzing a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate and (ii) hydrolyzing terminal alpha-1,2 mannose, alpha-1,3 mannose and/or alpha-1,6 mannose linkages, the molecular complex having gaa activity and including at least two polypeptides, each polypeptide having at least 85% sequence identity to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65), wherein before the contacting, at least one of the polypeptides includes phosphorylated n-glycans containing one or more mannose-1-phospho-6-mannose moieties. the mannosidase can be a family 38 glycosyl hydrolase (e.g., a canavalia ensiformis mannosidase or a yarrowia lipolytica mannosidase). the contacting can occur in a recombinant fungal cell expressing the mannosidase. this document also features a method of making a molecular complex that includes uncapped and demannosylated phosphorylated n-glycans. the method includes contacting a molecular complex with a mannosidase capable of hydrolyzing terminal alpha-1,2 mannose, alpha-1,3 mannose and/or alpha-1,6 mannose linkages, the molecular complex having gaa activity and comprising at least two polypeptides, each polypeptide having at least 85% sequence identity to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65), wherein at least one of the polypeptides includes prior to contacting, phosphorylated n-glycans comprising uncapped mannose-6-phosphate moieties. the mannosidase can be a family 47 glycosyl hydrolase (e.g., an aspergillus satoi mannosidase), a family 92 glycosyl hydrolase (e.g., a cellulosimicrobium cellulans mannosidase), or a family 38 glycosyl hydrolase (e.g., a canavalia ensiformis mannosidase). the contacting can occur in a recombinant fungal cell expressing the mannosidase. this document also features a method of making a molecular complex that includes uncapped and demannosylated phosphorylated n-glycans. the method includes contacting a molecular complex with a mannosidase capable of hydrolyzing a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate, the molecular complex having gaa activity and including at least two polypeptides, each polypeptide having at least 85% sequence identity to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65), wherein at least one of the polypeptides includes, before the contacting, one or more mannose-1-phospho-6-mannose moieties. the mannosidase can be a family 38 glycosyl hydrolase (e.g., a canavalia ensiformis mannosidase or a yarrowia lipolytica mannosidase). in another aspect, this document features a method of making a molecular complex that includes uncapped and demannosylated phosphorylated n-glycans. the method includes a) contacting a molecular complex with a mannosidase capable of hydrolyzing a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate to uncap mannose-6-phosphate moieties on at least one polypeptide in the molecular complex, the molecular complex having gaa activity and comprising at least two polypeptides, each polypeptide having at least 85% sequence identity to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65); and b) contacting the molecular complex with a mannosidase capable of hydrolyzing terminal alpha-1,2 mannose, alpha-1,3 mannose and/or alpha-1,6 mannose linkages. step (a) and step (b) can be catalyzed by two different enzymes or catalyzed by a single enzyme. the contacting steps can be performed together or separately, and in either order. the contacting can occur in a recombinant fungal host cell, the fungal host cell expressing a mannosidase capable of catalyzing step (a) and a mannosidase capable of catalyzing step (b). the contacting can occur in a recombinant fungal host cell, the fungal host expressing a mannosidase capable of catalyzing steps (a) and (b). any of the molecular complexes described herein that include at least one uncapped and demannosylated n-glycan can be used to contact a mammalian cell, wherein, after the contacting, the molecular complex is transported to the interior of the mammalian cell with enhanced efficiency. the mammalian cell can be a human cell. this document also features a method of transporting a molecular complex having gaa activity to the interior of a cell. the method includes contacting a mammalian cell with the molecular complex, the molecular complex including at least two polypeptides, each polypeptide having at least 85% sequence identity to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65); wherein phosphorylated n-glycans on at least one of the polypeptides have been uncapped and demannosylated as set forth in the methods described herein. the mammalian cell can be in vitro or in a mammalian subject. the mammalian cell can be a human cell. in another aspect, this document features a method of transporting a molecular complex having gaa activity to the interior of a cell. the method includes contacting a mammalian cell with the molecular complex that includes at least two polypeptides, each polypeptide having at least 85% sequence identity to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65), the molecular complex comprising at least one modification that results in enhanced ability of the molecular complex to be transported to the interior of a mammalian cell. the mammalian cell can be in vitro or in a mammalian subject. the mammalian cell can be a human cell. the modification can include any one of the following fused to at least one polypeptide in the molecular complex: a ligand for an extracellular receptor, a targeting domain that binds an extracellular domain of a receptor on the surface of a target cell, a urokinase-type plasminogen receptor, or the recognition domain of human insulin-like growth factor ii. in another aspect, this document features an isolated fungal cell that includes an exogenous nucleic acid encoding an alkaline protease having at least 85% sequence identity to the amino acid sequence set forth in seq id no:8. this document also features an isolated fungal cell comprising a nucleic acid encoding the gaa amino acid sequence set forth in seq id no:1 and a nucleic acid encoding an alkaline protease having at least 85% sequence identity to the amino acid sequence set forth in seq id no:8. the fungal cell produces a molecular complex having gaa activity and comprising at least two polypeptides, each polypeptide having at least 85% sequence identity to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65) by the alkaline protease. in some embodiments, the fungal cell further comprises a nucleic acid encoding a mannosidase, the mannosidase being capable of hydrolyzing a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate. in some embodiments, the fungal cell further includes a nucleic acid encoding a mannosidase, the mannosidase being capable of hydrolyzing a terminal alpha-1,2 mannose, alpha-1,3 mannose and/or alpha-1,6 mannose linkage. in some embodiments, the fungal cell further can include a nucleic acid encoding a mannosidase, the mannosidase being capable of (i) hydrolyzing a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate and (ii) hydrolyzing a terminal alpha-1,2 mannose, alpha-1,3 mannose and/or alpha-1,6 mannose linkage. any of such fungal cells further can include a nucleic acid encoding a polypeptide capable of promoting mannosyl phosphorylation and/or be genetically engineered to be deficient in och1 activity. unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the exemplary methods and materials are described below. all publications, patent applications, patents, genbank(r) accession nos, and other references mentioned herein are incorporated by reference in their entirety. in case of conflict, the present application, including definitions, will control. the materials, methods, and examples are illustrative only and not intended to be limiting. other features and advantages of the invention will be apparent from the following detailed description, and from the claims. description of drawings fig. 1 is a depiction of the amino acid sequence (seq id no:1) of human acid alpha glucosidase (gaa) after cleavage of the signal sequence. fig. 2a is a depiction of the nucleotide sequence of the open reading frame (orf) of dsba-cellulosimicrobium cellulans mannosidase 5 (ccman5) (seq id no:2). fig. 2b is a depiction of the amino acid sequence of the ccman5 polypeptide with the signal sequence in bold (seq id no: 3). fig. 2c is a depiction of the amino acid sequence of the ccman5 polypeptide without signal sequence (seq id no:4). the predicted molecular weight of the ccman5 polypeptide without the signal sequence is 173 kda. fig. 3a and 3b are a series of electropherograms depicting the n-glycan analysis of rhgaa treated with ccman5 and jbman. analysis was performed using dna sequencer-assisted, fluorophore-assisted carbohydrate electrophoresis (dsa-face). the y-axis represents the relative fluorescence units as an indication of the amount of each n-glycan structure. the x-axis represents the relative mobility of each n-glycan structure through a capillary. in both fig. 3a and fig. 3b, panel a is a reference sample containing the n-glycans released from rnaseb with pngasef. in fig. 3a, panels b and c contain the n-glycan analysis from hugaa (76 kd variant) before and after treatment, respectively, with ccman5 and jbman. in fig. 3b, panels b, c, and d contain the n-glycan analysis from hugaa 76 kd form, 95 kd form, and 110 kd form, respectively. fig. 4 is a line graph of the amount of glucose formed per minute with myozyme (•), 76 kda gaa (?), 95 kda gaa (?), and 110 kda gaa (?) using rabbit liver glycogen as substrate. fig. 5a contains two depictions of the glycogen levels (µg/mg protein) of individual mice in heart. fig. 5b contains two depictions of the glycogen levels (µg/mg protein) of individual mice in skeletal muscle. red dots are females, black dots are males. line represents the median of each group. fig. 6 contains a depiction of the amino acid sequence of the yarrowia lipolytica ams1 mannosidase (seq id no: 5). fig. 7 contains a depiction of the amino acid sequence of the aspergillus satoi mannosidase (seq id no:6). fig. 8 contains a depiction of the amino acid sequence of the cellulosimicrobium cellulans mannosidase 4 (ccman4, seq id no:7), with signal sequence in bold. the predicted molecular weight of the ccman4 polypeptide without the signal sequence is 184 kda. fig. 9 contains a depiction of the amino acid sequence of the aspergillus oryzae alkaline protease including the signal peptide (21 amino acids), pro-peptide (100 amino acids) and mature protein (282 amino acids) (seq id no:9). fig. 10 contains a depiction of the nucleotide sequence of the fusion construct containing the y. lipolytica codon optimized sequence encoding the a.oryzae alkaline protease (seq id no:10). restriction sites used for cloning are underlined. the nucleotide sequence encoding the linker is in bold and the nucleotide sequence encoding the his tag (10 his residues) is italicized. detailed description in general, this document provides isolated molecular complexes having acid alpha-glucosidase (gaa) activity and at least one modification that results in an enhanced ability to be transported to the interior of a mammalian cell. gaa is synthesized as a 110 kda precursor containing n-linked glycans. the precursor is proteolytically processed to remove the signal sequence and then further proteolytically processed to major species of 95 kda, 76 kda, and 70 kda. however, at least some of the peptides that are released from the precursor remain associated with the major species. see, for example, moreland et al., j. biol. chem., 280:6780-6791 (2005). thus, the molecular complexes having gaa activity described herein include at least two polypeptides (at least two, three, or four polypeptides) that are derived from proteolytic cleavage of the precursor molecule at one or more sites. at least two polypeptides in the molecular complex result from proteolytic cleavage at one or more sites in the precursor. for example, proteolysis of the amino acid sequence set forth in seq id no:1 can be between amino acid 50 and amino acid 74, e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65, to produce at least two polypeptides. a molecular complex containing two polypeptides is referred to as the 95 kda form herein. in some embodiments, at least three polypeptides in the molecular complex result from proteolytic cleavage at two or more sites in the precursor. for example, proteolysis of the amino acid sequence set forth in seq id no:1 can include, in addition to cleavage between amino acid 50 and amino acid 74 (e.g., between amino acid 50 and amino acid 74 or between amino acid 60 and amino acid 65), cleavage at one or more sites between amino acid 719 and amino acid 746 or cleavage at one or more sites between amino acid 137 and amino acid 151 of the amino acid sequence set forth in seq id no:1. a molecular complex containing three polypeptides is referred to as the 76 kda form herein. in some embodiments, at least four polypeptides in the molecular complex result from proteolytic cleavage at three or more sites in the precursor. for example, proteolysis of the amino acid sequence set forth in seq id no:1 can include, in addition to the cleavage between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65), cleavage at one or more sites between amino acid 719 and amino acid 746 of the amino acid sequence set forth in seq id no:1 and cleavage at one or more sites between amino acid 137 and amino acid 151 of the amino acid sequence set forth in seq id no:1. a molecular complex containing four polypeptides is referred to as the 70 kda form herein. it will be appreciated that cleavage can occur at one or more sites in one molecule, and that the site of cleavage can be different in different molecules. a commercially available protease mix containing proteases from aspergillus oryzae (e.g., from sigma or novozymescorp) can be used to cleave the amino acid sequence set forth in seq id no:1 between amino acids 50 and 74, e.g., between amino acids 56 and 68 or between amino acids 60 and 65. alternatively, an alkaline protease having at least 85% (e.g., at least 90%, 95%, 97%, 98%, 99%, or 100%) sequence identity to the alkaline protease from aspergillus oryzae (seq id no:8) can be used. for example, as described herein, a gaa polypeptide having the amino acid sequence set forth in seq id no:1 can be contacted with a protease having at least 85% sequence identity to the amino acid sequence set forth in seq id no:8 or seq id no: 9. seq id no: 8 is the amino acid sequence of the mature aspergillus oryzae alkaline protease. seq id no: 9 is the amino acid sequence of the aspergillus oryzae protease including the signal peptide, pro-peptide, and mature protein. the contacting can occur in vitro using protease that has been isolated from aspergillus oryzae or that has been recombinantly produced. alternatively, a fungal host can be engineered such that the gaa polypeptide and alkaline protease are both secreted into the culture medium, where the alkaline protease can cleave the amino acid sequence set forth in seq id no:1 between amino acid 50 and amino acid 74 (e.g., between amino acids 56 and 68 or between amino acid 60 and amino acid 65). the isolated molecular complexes described herein have at least one modification that results in an enhanced ability to be transported to the interior of a mammalian cell. non-limiting examples of modifications that enhance the ability of the complex of being transported to the interior of a mammalian cell include uncapping and demannosylation of phosphorylated n-glycans or peptide tags that facilitate transport. methods and materials are described herein for preparing molecular complexes containing tags or uncapped and demannosylated n-glycans. the isolated molecular complexes described herein are particularly useful for treating patients with pompe disease, including a patient diagnosed with pompe's disease, both infantile onset pompe's disease and late onset pompe's disease. pompe's disease results in an accumulation of glycogen in the lysosome due to a deficiency of gaa. the build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, including the heart, skeletal muscles, live, and nervous system. each of the polypeptide in the molecular complex have at least 85% sequence identity (e.g., at least 90%, 95%, 97%, 98%, 99%, or 100%) to a segment of the amino acid sequence set forth in seq id no: 1, each segment being derived by proteolysis of the amino acid sequence set forth in seq id no: 1 at one or more sites between amino acid 50 and amino acid 74 (e.g., between amino acid 56 and amino acid 68 or between amino acid 60 and amino acid 65). the percent identity between a particular amino acid sequence and the amino acid sequence set forth in seq id no: 1 can be determined as follows. first, the amino acid sequences are aligned using the blast 2 sequences (bl2seq) program from the stand-alone version of blastz containing blastp version 2.0.14. this stand-alone version of blastz can be obtained from fish & richardson's web site (e.g., www.fr.com/blast/) or the u.s. government's national center for biotechnology information web site (www.ncbi.nlm.nih.gov). instructions explaining how to use the bl2seq program can be found in the readme file accompanying blastz. bl2seq performs a comparison between two amino acid sequences using the blastp algorithm. to compare two amino acid sequences, the options of bl2seq are set as follows: -i is set to a file containing the first amino acid sequence to be compared (e.g., c:\seq1.txt); -j is set to a file containing the second amino acid sequence to be compared (e.g., c:\seq2.txt); -p is set to blastp; -o is set to any desired file name (e.g., c:\output.txt); and all other options are left at their default setting. for example, the following command can be used to generate an output file containing a comparison between two amino acid sequences: c:\bl2seq -i c:\seq1.txt -j c:\seq2.txt -p blastp -o c:\output.txt. if the two compared sequences share homology, then the designated output file will present those regions of homology as aligned sequences. if the two compared sequences do not share homology, then the designated output file will not present aligned sequences. similar procedures can be following for nucleic acid sequences except that blastn is used. once aligned, the number of matches is determined by counting the number of positions where an identical amino acid residue is presented in both sequences. the percent identity is determined by dividing the number of matches by the length of the full-length polypeptide amino acid sequence followed by multiplying the resulting value by 100. it is noted that the percent identity value is rounded to the nearest tenth. for example, 78.11, 78.12, 78.13, and 78.14 is rounded down to 78.1, while 78.15, 78.16, 78.17, 78.18, and 78.19 is rounded up to 78.2. it also is noted that the length value will always be an integer. it will be appreciated that a number of nucleic acids can encode a polypeptide having a particular amino acid sequence. the degeneracy of the genetic code is well known to the art; i.e., for many amino acids, there is more than one nucleotide triplet that serves as the codon for the amino acid. for example, codons in the coding sequence for a given gaa polypeptide can be modified such that optimal expression in a particular species (e.g., bacteria or fungus) is obtained, using appropriate codon bias tables for that species. in one embodiment, a molecular complex can include at lea
BR112014022624A 2012-03-15 2013-03-14 métodos e materiais para tratamento de doença de pompe BR112014022624A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611485P 2012-03-15 2012-03-15
PCT/IB2013/000912 WO2013136189A2 (en) 2012-03-15 2013-03-14 Methods and materials for treatment of pompe's disease

Publications (1)

Publication Number Publication Date
BR112014022624A2 true BR112014022624A2 (pt) 2017-07-11

Family

ID=48626475

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014022624A BR112014022624A2 (pt) 2012-03-15 2013-03-14 métodos e materiais para tratamento de doença de pompe

Country Status (11)

Country Link
US (2) US9249399B2 (pt)
EP (2) EP3628326B1 (pt)
JP (1) JP6194324B2 (pt)
KR (2) KR20190114003A (pt)
CN (1) CN104379162B (pt)
AU (1) AU2013234042B2 (pt)
BR (1) BR112014022624A2 (pt)
CA (1) CA2867237C (pt)
HK (1) HK1200348A1 (pt)
RU (1) RU2644258C2 (pt)
WO (1) WO2013136189A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170091174A (ko) * 2007-04-03 2017-08-08 옥시레인 유케이 리미티드 분자의 글리코실화
KR101824743B1 (ko) 2009-09-29 2018-02-05 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
DK2501805T3 (en) 2009-11-19 2019-04-15 Oxyrane Uk Ltd Yeast strains producing mammalian-like complex N-Glycans
EP2622089B1 (en) 2010-09-29 2023-11-01 Oxyrane UK Limited De-mannosylation of phosphorylated n-glycans
BR112013007616B1 (pt) 2010-09-29 2023-01-24 Oxyrane Uk Limited Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
KR20190114003A (ko) 2012-03-15 2019-10-08 옥시레인 유케이 리미티드 폼페병의 치료를 위한 방법 및 물질
US11040114B2 (en) 2015-12-24 2021-06-22 Oxyrane Uk Limited Human alpha-N-acetylgalactosaminidase polypeptide
SG11201808592PA (en) * 2016-03-30 2018-10-30 Amicus Therapeutics Inc Method for selection of high m6p recombinant proteins
CN109196097A (zh) * 2016-03-30 2019-01-11 阿米库斯治疗学公司 用于选择高m6p重组蛋白的方法
AU2017239641A1 (en) * 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
EA202290114A1 (ru) * 2017-03-30 2022-03-29 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
CA3127162A1 (en) 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
AU2022218792A1 (en) * 2021-02-11 2023-08-24 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
JPS5754588A (en) 1980-09-19 1982-04-01 Eiji Ichijima Alpha-mannosidase
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
DK0585368T3 (da) 1991-04-25 1998-03-16 Univ Brown Res Found Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5834251A (en) 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
WO1997044470A1 (en) 1996-05-21 1997-11-27 Novo Nordisk A/S Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
WO1998001535A1 (en) 1996-07-05 1998-01-15 Novo Nordisk A/S Method for the production of polypeptides
AU3255397A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
DK0975775T3 (da) 1997-04-23 2004-07-26 Vlaams Interuniv Inst Biotech Regulatorisk system til inducerbar ekspression af gener med lambdapromotorer
US7442772B2 (en) 1997-12-03 2008-10-28 Genentech, Inc. Antibodies to PRO361 polypeptide
AU2241699A (en) 1998-01-27 1999-08-09 Board Of Regents Of The University And Community College System Of Nevada, The Expression of proteolytically-sensitive peptides
WO2001042462A2 (en) 1999-12-08 2001-06-14 National University Of Singapore Phospholipase a2 inhibitory peptides from python reticulatus
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
WO2001049830A2 (en) 1999-12-30 2001-07-12 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
WO2001088143A1 (fr) 2000-05-17 2001-11-22 Mitsubishi Pharma Corporation Procede d'elaboration de proteine avec reduction de chaine saccharose acide, et glycoproteine resultante
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
AU2001277658B2 (en) 2000-06-30 2006-10-19 Research Corporation Technologies, Inc. Protein glycosylation modification in pichia pastoris
KR100386836B1 (ko) 2000-08-31 2003-06-09 동국제약 주식회사 재조합 인체 부갑상선 호르몬을 생산하는 형질전환효모 및재조합 인체 부갑상선 호르몬의 생산방법
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4774496B2 (ja) 2001-06-14 2011-09-14 独立行政法人産業技術総合研究所 α−マンノシダーゼ
JP4742191B2 (ja) 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
ES2327905T3 (es) 2001-10-01 2009-11-05 Dyax Corp. Vectores de presentacion eucariotas multi-cadena y usos de los mismos.
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US8932825B2 (en) 2001-12-27 2015-01-13 Glycofi Inc. Method to engineer mammalian-type carbohydrate structures
US7141653B2 (en) 2002-03-29 2006-11-28 Schering Corporation Human monoclonal antibodies to interleukin-5
ATE420198T1 (de) 2002-04-26 2009-01-15 Kirin Pharma Kk Methylotrophe hefe,die eine zuckerkette eines säugers herstellt
IL165717A0 (en) 2002-06-26 2006-01-15 Flanders Interuniversity Inst A strain of methylotrophic yeast for producing proteins
DE60334109D1 (de) 2002-06-29 2010-10-21 Leadbio Inc Yapsin-mangelmutantenstamm von hansenula polymorpha sowie verfahren zur herstellung rekombinanter proteine damit
KR100470978B1 (ko) 2003-01-02 2005-03-10 한국생명공학연구원 앱신 다중 결손 효모 변이 균주 및 이를 이용한 재조합 단백질의 생산 방법
RU2407796C2 (ru) * 2003-01-22 2010-12-27 Гликарт Биотекнолоджи АГ КОНСТРУКЦИИ СЛИЯНИЯ И ИХ ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ АНТИТЕЛ С ПОВЫШЕННЫМИ АФФИННОСТЬЮ СВЯЗЫВАНИЯ Fc-РЕЦЕПТОРА И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
AU2012206984B2 (en) 2003-02-11 2015-07-09 Takeda Pharmaceutical Company Limited Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE)
JP4259169B2 (ja) 2003-04-16 2009-04-30 昭和産業株式会社 新規α−１，２−マンノシダーゼおよびその遺伝子、ならびに該酵素を用いたα−マンノシル糖化合物の製造方法
US7259255B2 (en) 2003-06-25 2007-08-21 E. I. Du Pont De Nemours And Company Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast
US7259007B2 (en) 2003-12-24 2007-08-21 Glycofi, Inc. Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins
ATE465250T1 (de) 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
AU2005233387B2 (en) 2004-04-15 2011-05-26 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
JP4954866B2 (ja) 2004-04-29 2012-06-20 グライコフィ， インコーポレイテッド 糖タンパク質の作製においてアルファ−マンノシダーゼ抵抗性グリカンを減少させるか又は排除する方法
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20060014264A1 (en) 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
EA012617B1 (ru) * 2005-03-24 2009-10-30 ДСМ АйПи АССЕТС Б.В. Способ микробиального производства ценного соединения
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CA2604917A1 (en) 2005-04-14 2007-01-25 Csir Recombinant yeasts for synthesizing epoxide hydrolases
EP1934605B1 (en) 2005-09-22 2014-03-26 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20080081035A1 (en) * 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
US20110076752A1 (en) 2007-02-09 2011-03-31 Medimmune, Llc Antibody library display by yeast cell plasma membrane
KR20170091174A (ko) 2007-04-03 2017-08-08 옥시레인 유케이 리미티드 분자의 글리코실화
US8569032B2 (en) 2007-05-18 2013-10-29 Tokyo Metropolitan Institute Of Medical Science Proteins having acquired A-galactosidase activity
AU2009205978B2 (en) 2008-01-18 2014-04-10 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US20100311122A1 (en) 2008-02-20 2010-12-09 Glycofi, Inc Vectors and yeast strains for protein production
US20110223147A1 (en) * 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
EP2921551A3 (en) 2009-02-26 2015-12-02 GlaxoSmithKline LLC Host cells and methods of use
KR101824743B1 (ko) 2009-09-29 2018-02-05 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
DK2501805T3 (en) 2009-11-19 2019-04-15 Oxyrane Uk Ltd Yeast strains producing mammalian-like complex N-Glycans
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
BR112012018163A2 (pt) 2010-01-21 2019-09-24 Oxyrane Uk Ltd métodos e composições para exibição de um polipeptídeo sobre a superfície de uma célula de levredura
US20120135461A1 (en) 2010-07-30 2012-05-31 William James Cook Production of glycoproteins with reduced o-glycosylation comprising the use of an alpha-1,2-mannosidase
BR112013007616B1 (pt) 2010-09-29 2023-01-24 Oxyrane Uk Limited Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
EP2622089B1 (en) * 2010-09-29 2023-11-01 Oxyrane UK Limited De-mannosylation of phosphorylated n-glycans
US20150031081A1 (en) 2011-12-30 2015-01-29 Oxyrane Uk Limited Methods and materials for reducing degradation of recombinant proteins
KR20190114003A (ko) 2012-03-15 2019-10-08 옥시레인 유케이 리미티드 폼페병의 치료를 위한 방법 및 물질

Also Published As

Publication number Publication date
KR102028228B1 (ko) 2019-10-04
EP3628326A1 (en) 2020-04-01
EP2825193A2 (en) 2015-01-21
WO2013136189A3 (en) 2014-02-20
JP6194324B2 (ja) 2017-09-06
JP2015516148A (ja) 2015-06-11
US20160279254A1 (en) 2016-09-29
EP3628326C0 (en) 2024-02-28
WO2013136189A2 (en) 2013-09-19
AU2013234042B2 (en) 2017-11-02
RU2014139953A (ru) 2016-05-20
US10648044B2 (en) 2020-05-12
AU2013234042A1 (en) 2014-10-23
EP3628326B1 (en) 2024-02-28
CN104379162B (zh) 2017-03-15
HK1200348A1 (en) 2015-08-07
CA2867237A1 (en) 2013-09-19
EP2825193B1 (en) 2019-11-13
RU2644258C2 (ru) 2018-02-08
US9249399B2 (en) 2016-02-02
KR20190114003A (ko) 2019-10-08
CN104379162A (zh) 2015-02-25
US20130243746A1 (en) 2013-09-19
KR20140135802A (ko) 2014-11-26
CA2867237C (en) 2024-01-02

Similar Documents

Publication Publication Date Title
BR112014022624A2 (pt) métodos e materiais para tratamento de doença de pompe
CA2882501C (en) Compositions comprising alpha mannosidase and uses thereof
CA2731203C (en) Constructs and methods for the production and secretion of polypeptides
JP2017035091A (ja) 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ
US20080220473A1 (en) Endo-N-Acetyl-Beta-D-Glucosaminidase Enzymes of Filamentous Fungi
JP2015516148A5 (pt)
AU2019202865B2 (en) Peptide linkers for polypeptide compositions and methods for using same
CN114350639B (zh) 一种密码子优化的透明质酸水解酶基因及其表达
BR112020012346A2 (pt) proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma
Meghdari et al. Carboxyl-terminal truncations alter the activity of the human α-galactosidase A
KR20180055888A (ko) 변형된 라이소좀 단백질 및 그의 제조 방법
US20220298514A1 (en) Aav-zyme and use for infusion replacement therapy
Leng et al. Cloning, functional expression and purification of endo-β-galactosidase from Flavobacterium keratolyticus
Kelo Catalytic and therapeutic characteristics of human recombinant glycosylasparaginase and bacterial L-asparaginases
Carroll Evolution of Lysosomal Proteins
OA16639A (en) Modified acid alpha glucosidase with accelerated processing.
CARSANA et al. Evolution of Vertebrate Ribonucleases: Ribonuclease A

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: OXYRANE UK LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements